Entering text into the input field will update the search result below

Nektar Therapeutics EPS beats by $0.16, beats on revenue

Nov. 05, 2020 4:25 PM ETNektar Therapeutics (NKTR) StockNKTRBy: Meghavi Singh, SA News Editor
  • Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16.
  • Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the recognition of $50.0M in total milestones from Bristol-Myers Squibb related to the start of two new registrational trials of bempegaldesleukin plus Opdivo® in adjuvant melanoma and muscle-invasive bladder cancer.
  • Product sales: $5.7M (+1.8%).
  • Cash and investments in marketable securities of ~$1.2B.
  • Press Release

Recommended For You

More Trending News

About NKTR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NKTR--
Nektar Therapeutics